Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.
SCHIZOPHRENIA (AND OTHER PSYCHOTIC DISORDERS)
COGNITIVE-BEHAVIOUR THERAPY RESEARCH PROGRAMME

A thesis presented in partial fulfilment
of the requirements for the degree of

Master of Arts in Psychology

at Massey University

Ruth Gillingham

2005
Abstract

The present study evaluated the effectiveness of a treatment that combined techniques from Cognitive-Behaviour Therapy (CBT) and Acceptance and Commitment Therapy (ACT) to alleviate the psychological distress and symptom severity resultant from psychotic-type disorders. This treatment (EVoLVE Therapy; an acronym for Exposing Virtues of Living Valued Existences) was designed to primarily target the psychological distress associated with psychotic disorders and secondarily to facilitate improvement in psychotic-type symptoms. Participants in this study were selected based on previous diagnoses of schizophrenia, schizoaffective, and other psychiatric disorders with psychotic features. Seven participants, who had each been long-term consumers of mental health services, completed 10 weeks of therapy. Post-graduate students, in training to become professional psychologists, delivered supervised therapy using a structured treatment manual written by the researcher. Pre-treatment, post-treatment and 5-week follow-up data were collected, using a variety of measures to assess the effectiveness of treatment. Results were quite positive overall, with some clients making considerable improvements in a number of domains. All 7 participants showed a decrease in symptom severity after treatment. In addition, 6 out of the 7 participants reported an improved quality of life following treatment. Marked improvement in negative affect was also evident, with a slight improvement in positive affect noted.
Acknowledgements

First, I would like to thank the eight participants who took part in this research. This thesis would not have been possible without you. It was a pleasure getting to know you, and I wish you well as you strive toward living lives of quality and value despite having a chronic mental illness.

I would like to acknowledge and thank my supervisor – Dr Patrick Dulin. Thank you for your valuable guidance and supervision during the clinical practice, for your clear editing, and for being there to support, encourage, and motivate me throughout this project. Thank you also to my second supervisor – Professor Ian Evans – for your support and guidance, especially with the design of the study and the EVoLVE Therapy manual. Thanks to you both for your unwavering belief in me, and my ability to do this project.

I would like to acknowledge the staff at SF Manawatu, in particular, Christine Zander, Jan Holdaway, and Elizabeth Green. Thanks Christine for proposing this project to Ian. And, thank you to all three of you for welcoming my fellow therapists and I so warmly into the SF fold. You provide wonderful support to those whose lives are affected by mental illness.

Thank you also to the independent assessor for this research – Renée Seebeck; and to my fellow therapists: Rebekah Jourdain, Kelly Richardson, Christina Robinson, and Amie Bingham. Without your help and support this project would have been much more difficult. In addition, I would like to acknowledge the cultural consultants for this project, Mr Turoa Haronga and Dr Paul Hirini. Thanks also to all the wonderful staff at the Psychology Clinic, Turitea, Massey University, for your assistance and support during the running of the treatment programme, and for providing the opportunity to conduct my research in your clinic. Thank you to Dr Shane Harvey for his assistance with aspects of the results section. Research approval was obtained from the Massey University Ethics Committee and the Manawatu/Whanganui Ethics Committee.

I would like to make special mention of my parents, Joan and Tom, and my mother-in-law, Rona. Thank you for the quality care of our children when needed, and for your love and support. Also, a special thank you to the family and friends who have supported and encouraged me throughout this thesis project – in particular, Bill and Annette, Tom, Marie Strachan, Edith and Heidi, Anna and Colin, Renée and Andy, Phillipa and Nigel, Jackie and Paul, Annette and Des, and Simone.

Lastly, but by no means least, I would like to thank my wonderful husband, Murray, and our three beautiful children, Dean, Craig, and Kelly. Thank you Murray for your love, friendship, support, encouragement, technical and computing assistance, your belief in me, and for being an amazing father to our children. To our special children, thank you. I am so proud of you.
### Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title Page</td>
<td>i</td>
</tr>
<tr>
<td>Abstract</td>
<td>ii</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>iii</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>iv</td>
</tr>
<tr>
<td>List of Tables</td>
<td>ix</td>
</tr>
<tr>
<td>List of Figures</td>
<td>x</td>
</tr>
<tr>
<td><strong>CHAPTER 1. INTRODUCTION</strong></td>
<td>1</td>
</tr>
<tr>
<td>1.0 Project Overview</td>
<td>1</td>
</tr>
<tr>
<td>1.1 Defining Schizophrenia</td>
<td>3</td>
</tr>
<tr>
<td>1.2 Mood Disorders</td>
<td>6</td>
</tr>
<tr>
<td>1.3 Epidemiology</td>
<td>10</td>
</tr>
<tr>
<td>1.3.1 Age and gender differences</td>
<td>10</td>
</tr>
<tr>
<td>1.3.2 Cultural and socio-economic factors</td>
<td>10</td>
</tr>
<tr>
<td>1.3.3 Comorbid disorders</td>
<td>13</td>
</tr>
<tr>
<td>1.4 Psychological Distress and Schizophrenia</td>
<td>13</td>
</tr>
<tr>
<td>1.5 Aetiology</td>
<td>14</td>
</tr>
<tr>
<td>1.5.1 Stress-diathesis model</td>
<td>15</td>
</tr>
<tr>
<td>1.5.2 Cognitive theory of schizophrenia</td>
<td>17</td>
</tr>
<tr>
<td>1.6 Course and Outcome</td>
<td>19</td>
</tr>
<tr>
<td>1.7 Emotions</td>
<td>21</td>
</tr>
<tr>
<td>1.7.1 Negative emotions</td>
<td>21</td>
</tr>
</tbody>
</table>
1.7.2  Health engendering effects of positive emotions................. 22

1.8  Quality of Life........................................................................ 23

1.9  Treatment............................................................................. 24
  1.9.1  History............................................................................ 24
  1.9.2  Medication....................................................................... 25
  1.9.3  Psychological treatments................................................. 26

1.10  Cognitive Behaviour Therapy............................................... 28

1.11  Cognitive Behaviour Therapy for Schizophrenia..................... 29
  1.11.1  Summary of effectiveness............................................... 29
  1.11.2  Background and major aims.......................................... 31
  1.11.3  Combination cognitive-behavioural therapy...................... 33

1.12  Manualised Cognitive-Behavioural Therapy for Schizophrenia..... 35

1.13  Brief Therapy....................................................................... 37

1.14  Acceptance and Commitment Therapy.................................... 38

1.15  EVoLVE Therapy............................................................... 43

1.16  Components of EVoLVE Therapy and their Rationale............. 44
  1.16.1  Session 1...................................................................... 44
  1.16.2  Session 2...................................................................... 45
  1.16.3  Session 3...................................................................... 47
  1.16.4  Session 4...................................................................... 48
  1.16.5  Session 5...................................................................... 49
  1.16.6  Session 6...................................................................... 51
  1.16.7  Session 7...................................................................... 53
  1.16.8  Session 8...................................................................... 54
1.16.9 Session 9

1.16.10 Session 10

1.17 The Present Study

1.17.1 Goals of the present study

CHAPTER 2. METHOD

2.0 Design

2.1 Setting

2.2 Participants

2.2.1 Referral and selection

2.2.2 Inclusion/Exclusion criteria

2.3 Assessment

2.4 Assessor

2.5 Semi-Structured Interview

2.6 Self-Report Measures

2.7 Therapists

2.8 Treatment Manual

2.9 Intervention

2.10 Treatment Materials

2.11 Treatment Integrity

2.12 Procedure

2.13 Ethical Considerations

2.13.1 Access to participants

2.13.2 Informed consent
CHAPTER 3. RESULTS

3.0 An Overview of the Results Section

3.1 Participant Characteristics

3.2 Pre- and Post-Treatment, and 5-Week Follow-Up Assessment Results

3.2.1 Brief Psychiatric Rating Scale Expanded Version 4.0

3.2.2 Brief Symptom Inventory

3.2.3 Revised Schizophrenia Quality of Life Questionnaire

3.3 Positive and Negative Affect Schedule (PANAS) Scores

3.4 Individual PANAS Profiles Across Time

CHAPTER 4. DISCUSSION

4.0 Summary of the Findings

4.1 Limitations of the Present Study

4.2 Recommendations for Future Research

4.3 Conclusion

References
APPENDICES........................................................................................................ 151

Appendix A – DSM-IV Criteria for Schizophrenia........................................ 152

Appendix B – Memorandum of Understanding........................................... 153

Appendix C – Information sheet for participants........................................ 155

Appendix D – Assessor’s Confirmation of Participant’s Ability to Provide Informed Consent Form.................................................. 158

Appendix E – Research Consent Form.......................................................... 159

Appendix F – My Contract Form................................................................. 160

Appendix G – Sociodemographic Questionnaire......................................... 161

Appendix H – Brief Psychiatric Rating Scale (BPRS).................................... 162

Appendix I – Brief Symptom Inventory (BSI).............................................. 171

Appendix J – Positive and Negative Affect Schedule (PANAS).................... 173

Appendix K – Revised Schizophrenia Quality of Life Questionnaire (SQLS-R4).................................................................................. 174

Appendix L – Client EVoLVE sessions......................................................... 178

Appendix M – EVoLVE Therapy Evaluation Form...................................... 180

Appendix N – EVoLVE Therapy Treatment Manual.................................... 184
# List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.</td>
<td>Summary of the Measures Used.</td>
<td>73</td>
</tr>
<tr>
<td>Table 2.</td>
<td>Summary of Participant Characteristics</td>
<td>87</td>
</tr>
<tr>
<td>Table 3.</td>
<td>Total Brief Psychiatric Rating Scale (BPRS) Scores for Pre-Treatment, Post-Treatment, and 5-Week Follow-Up</td>
<td>88</td>
</tr>
<tr>
<td>Table 4.</td>
<td>Revised Schizophrenia Quality of Life Questionnaire (SQLS-R4) Group Mean Scores and Standard Deviations at Pre-Treatment, 1-Week Post-Treatment and 5-Week Follow-Up</td>
<td>103</td>
</tr>
<tr>
<td>Table 5.</td>
<td>Scores on the Revised Schizophrenia Quality of Life Questionnaire (SQLS-R4)</td>
<td>104</td>
</tr>
<tr>
<td>Table 6.</td>
<td>PANAS Group Mean Scores and Standard Deviations Across Time for the Positive Scale</td>
<td>106</td>
</tr>
<tr>
<td>Table 7.</td>
<td>PANAS Group Mean Scores and Standard Deviations Across Time for the Negative Scale</td>
<td>107</td>
</tr>
</tbody>
</table>
### List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.</td>
<td>Cognitive behaviour therapy for schizophrenia model (D. Turkington and D. Kingdon Presentation at the meeting on Psychological Approaches to the Management of Psychosis, Withington Hospital, University of Manchester, 1994). Reprinted from McGovern and Turkington (2001) p.163.</td>
<td>35</td>
</tr>
<tr>
<td>Figure 2.</td>
<td>Brief Psychiatric Rating Scale (BPRS) Total score at pre- and post-intervention and 5-week follow-up for each participant.</td>
<td>89</td>
</tr>
<tr>
<td>Figure 3.</td>
<td>Brief Psychiatric Rating Scale (BPRS) Paranoid Disturbance Factor score for each participant at pre- and post-intervention and at 5-week follow-up.</td>
<td>90</td>
</tr>
<tr>
<td>Figure 4.</td>
<td>Brief Psychiatric Rating Scale (BPRS) Thought Disturbance Factor score for each participant at pre- and post-intervention and at 5-week follow-up.</td>
<td>91</td>
</tr>
<tr>
<td>Figure 5.</td>
<td>Brief Psychiatric Rating Scale (BPRS) Withdrawal/Motor Retardation Factor score for each participant at pre- and post-intervention and at 5-week follow-up.</td>
<td>92</td>
</tr>
<tr>
<td>Figure 6.</td>
<td>Brief Psychiatric Rating Scale (BPRS) Anxiety/Depression Factor score for each participant at pre- and post-intervention and at 5-week follow-up.</td>
<td>93</td>
</tr>
<tr>
<td>Figure 7.</td>
<td>Mean group scores on the four Brief Psychiatric Rating Scale (BPRS) Factors at pre- and post-treatment and 5-week follow-up.</td>
<td>94</td>
</tr>
<tr>
<td>Figure 8.</td>
<td>Mean group Total Brief Psychiatric Rating Scale (BPRS) score at pre- and post-treatment and 5-week follow-up.</td>
<td>95</td>
</tr>
<tr>
<td>Figure 9.</td>
<td>Brief Symptom Inventory (BSI) group mean scores on all Primary Symptom Dimensions and Global Indices at pre- and post-treatment and 5-week follow-up.</td>
<td>96</td>
</tr>
<tr>
<td>Figure 10.</td>
<td>Brief Symptom Inventory (BSI) Primary Symptom Dimension scores and Global Indices scores for participant 1 at pre- and post-treatment and at 5-week follow-up.</td>
<td>97</td>
</tr>
</tbody>
</table>
Figure 11. Brief Symptom Inventory (BSI) Primary Symptom Dimension scores and Global Indices scores for participant 2 at pre- and post-treatment and at 5-week follow-up.

Figure 12. Brief Symptom Inventory (BSI) Primary Symptom Dimension scores and Global Indices scores for participant 3 at pre- and post-treatment and at 5-week follow-up.

Figure 13. Brief Symptom Inventory (BSI) Primary Symptom Dimension scores and Global Indices scores for participant 4 at pre- and post-treatment and at 5-week follow-up.

Figure 14. Brief Symptom Inventory (BSI) Primary Symptom Dimension scores and Global Indices scores for participant 5 at pre- and post-treatment and at 5-week follow-up.

Figure 15. BSI Primary Symptom Dimension scores and Global Indices scores for participant 6 at pre- and post-treatment and at 5-week follow-up.

Figure 16. BSI Primary Symptom Dimension scores and Global Indices scores for participant 7 at pre- and post-treatment and at 5-week follow-up.

Figure 17. Revised Schizophrenia Quality of Life Questionnaire (SQLS-R4) scores for each participant at pre-treatment (baseline), post-treatment (F1), and follow-up (F2).

Figure 18. Positive and Negative Affect Schedule (PANAS) group mean scores pre-treatment, during baseline and treatment, and 5-week follow-up.

Figure 19. Scores on the Positive and Negative Affect Schedule (PANAS) across assessment and treatment sessions for participant 1.

Figure 20. Scores on the Positive and Negative Affect Schedule (PANAS) across assessment and treatment sessions for participant 2.

Figure 21. Scores on the Positive and Negative Affect Schedule (PANAS) across assessment and treatment sessions for participant 3.

Figure 22. Scores on the Positive and Negative Affect Schedule (PANAS) across assessment and treatment sessions for participant 4.

Figure 23. Scores on the Positive and Negative Affect Schedule (PANAS) across assessment and treatment sessions for participant 5.
Figure 24. Scores on the Positive and Negative Affect Schedule (PANAS) across assessment and treatment sessions for participant 6.............................. 112

Figure 25. Scores on the Positive and Negative Affect Schedule (PANAS) across assessment and treatment sessions for participant 7.............................. 113